key: cord-1048953-1pl30ei7 authors: Castañeda-Mogollón, Daniel; Kamaliddin, Claire; Oberding, Lisa; Liu, Yan; Mohon, Abu Naser; Faridi, Rehan Mujeeb; Khan, Faisal; Pillai, Dylan title: A metagenomics workflow for SARS-CoV-2 identification, co-pathogen detection, and overall diversity date: 2021-11-03 journal: J Clin Virol DOI: 10.1016/j.jcv.2021.105025 sha: 4f622bfe78d8309ffbe2e980fe6d57db9529ab28 doc_id: 1048953 cord_uid: 1pl30ei7 An unbiased metagenomics approach to virus identification can be essential in the initial phase of a pandemic. Better molecular surveillance strategies are needed for the detection of SARS-CoV-2 variants of concern and potential co-pathogens triggering respiratory symptoms. Here, a metagenomics workflow was developed to identify the metagenome diversity by SARS-CoV-2 diagnosis (n(positive)=65; n(negative)= 60), symptomatology status (n(symptomatic)=71; n(asymptomatic)=54) and anatomical swabbing site (n(nasopharyngeal)=96; n(throat)=29) in 125 individuals. Furthermore, the workflow was able to identify putative respiratory co-pathogens, and the SARS-CoV-2 lineage across 29 samples. The diversity analysis showed a significant shift in the DNA-metagenome by symptomatology status and anatomical swabbing site. Additionally, metagenomic diversity differed between SARS-CoV-2 infected and uninfected asymptomatic individuals. While 31 co-pathogens were identified in SARS-CoV-2 infected patients, no significant increase in pathogen or associated reads were noted when compared to SARS-CoV-2 negative patients. The Alpha SARS-CoV-2 VOC and 2 variants of interest (Zeta) were successfully identified for the first time using a clinical metagenomics approach. The metagenomics pipeline showed a sensitivity of 86% and a specificity of 72% for the detection of SARS-CoV-2. Clinical metagenomics can be employed to identify SARS-CoV-2 variants and respiratory co-pathogens potentially contributing to COVID-19 symptoms. The overall diversity analysis suggests a complex set of microorganisms with different genomic abundance profiles in SARS-CoV-2 infected patients compared to healthy controls. More studies are needed to correlate severity of COVID-19 disease in relation to potential disbyosis in the upper respiratory tract. A metagenomics approach is particularly useful when novel pandemic pathogens emerge. Individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present with multiple symptoms ranging in severity from asymptomatic/mild cases to severe pneumonia and death 1 . The poor specificity of COVID-19 clinical presentation means that extensive screening must be performed for individuals presenting fever or respiratory infection symptoms. Current screening strategies are based on nasopharyngeal swabs (NPS) or throat swabs (TS) and molecular diagnostics targeting specific SARS-CoV-2 genes. Recently, multiple SARS-CoV-2 variants have been identified through whole-genome sequencing (WGS) approaches, including variant of concern (VOC) Alpha, Beta, Gamma, Epsilon, and Delta 2 . Metagenomic Next-Generation Sequencing (mNGS) provides an unbiased method for identification of all taxonomic ranks in a sample using a single sequencing run 3, 4 . Compared to traditional microbial culture-based methods, mNGS can be used as a robust diagnostic tool, which is faster, more sensitive, and allows for the identification of unculturable organisms [5] [6] [7] . At the time of writing, the metagenome associated with SARS-CoV-2 infection remains poorly characterized. Additionally, current COVID-19 6 co-infection studies could be biased by public health guidelines (i.e. social distancing, masks) 8-14, as prepandemic studies have found S. pneumoniae, P. aeruginosa, and H. influenzae to be the three most common bacterial co-pathogens 15 . While the aforementioned studies offer clues to understand the microbial diversity associated with COVID-19, a study of the metagenome and metatranscriptome (hereinafter referred as DNA-metagenome and RNA-metagenome) associated with COVID-19 and SARS-CoV-2 asymptomatic infection is necessary. This study investigated the metagenome from upper respiratory samples by SARS-Cov-2 diagnosis, symptomatology, and anatomical sampling site ( Figure 1 ). Moreover, we evaluated the performance of mNGS for SARS-CoV-2 diagnosis, and its ability to identify SARS-CoV-2 mutants. A total of 125 clinical NPS and TS samples were collected and tested by Alberta Precision Laboratories between March 2020 and February 2021. Swabs were performed by trained personnel as part of the Alberta COVID-19 testing program. Symptom screening was based on patient reporting to the sampling nurse using the standard APL procedure (Supplementary methods). Ethical approval was obtained from Conjoint Health Research Ethics Board (CHREB) of the University of Calgary (REB 20-0567, REB 20-0402). All archived specimens were de-identified prior to analysis in this study. Informed consent was waived by the ethics board. Samples were randomized in extraction batches including internal controls to assess the metagenome Primer spiked enrichment was adapted from published protocols 16, 17 . cDNA synthesis was performed from 5 µL of extracted RNA (DNA-free) using the NEBNext Ultra II first strand and second strand synthesis modules (E7771 and E6111, NEB, MA, USA) (Supplementary Methods). Internal controls were used to assess the overall performance of the mNGS pipeline, as well as to generate a background model to remove environmental contamination. The product from the cDNA synthesis step were used in the library preparation step, and sequenced in a Illumina instrument Organism detection was performed using sequence analysis of metagenomic data using the IDseq server-based pipeline 18 . The quality control step performed a priori subtraction of host sequences by using STAR (Spliced Transcripts Alignment to a Reference) 19 , followed by Trimmomatic 20 to trim Illumina adapters. Low-quality and low-complexity reads were removed followed by taxonomic identification (detailed in Supplementary Methods). Two filters were applied to increase the analytical specificity of the workflow for species identification: (i) a Z-score ≥ 2.0, and (ii) a minimum of 10 reads aligned to the NCBI Nucleotide database. To determine sample diversity, an alpha-and beta-diversity analysis was performed across each group (detailed in Supplementary Methods). In addition a diversity analysis was stratified by SARS-CoV-2-positive samples with Ct values above 30. Samples with reads mapped to the SARS-CoV-2 genome were submitted to IDseq for genome assembly and variant calling. SNPs were called for variation analysis and compared against the reference genome using the default parameters. For sample lineage characterization, genomes with a minimum breadth of coverage of 50% were submitted to the Pangolin online sequence aligner 21 (based on the GISAID consortium https://www.gisaid.org/ -available sequences on March 27 th , 2021). Lineage characterization for samples between 25% to 50% breadth of coverage were estimated by the closest clade in the phylogenomics tree (Supplementary Methods). Species were identified based on Z-score ≥ 2 and > 10 reads mapped to a given taxa. The complete list of species that were screened as part of the putative respiratory pathogen panel is available in Supplementary Methods. Proportion of identified organism were compared using Fisher's exact test with Benjamini-Hocheberg correction. Details of the statistical analysis and software are available in the Supplementary Methods. A total of 823,317,205 and 765,758,597 non-human reads were sequenced from the metagenome and metatranscriptome, respectively (1.07 DNA to cDNA ratio). An average of 20,983,714 ± 358,651 and 20,479,932 ± 469,732 reads were identified respectively for the DNA-metagenome and the RNAmetagenome. No significance was found amongst the non-human reads by SARS-CoV-2 diagnosis (Figure S1a) nor by anatomical sampling site ( Figure S1b ). Significantly higher human reads were observed amongst NPS than TS in the cDNA number of reads ( Figure S1c ). Amongst the SARS-CoV-2 infected individuals, an average of 0.02% of reads were mapped to the SARS-CoV-2 genome from the original number of raw cDNA reads. The DNA-metagenome diversity analysis of significance was performed ( Table 1) Table 1) . The diversity analysis of significance was also performed for the RNA-metagenome of bacteriophages (Table S1 ). The beta-diversity analysis of the bacteriophages RNA-metagenome showed significant results in its quantitative and qualitative analysis by anatomical sampling site, symptomatology, and the SARS-CoV-2 status amongst the NPS-asymptomatic cohort (Figure 3a The DNA and RNA-metagenome results were screened for presence of potential pathogens. influenzae, C. pneumoniae, human coronavirus HKU1 and NL63). The prevalence of each screened potential co-pathogen was compared between SARS-CoV-2 positive (COVID-19 patients) and uninfected patients for NPS (Table S3 ) and TS (Table S4 ). Only D. pigrum was significantly more prevalent in COVID-19 positive patients. No significant rPM differences were observed for the rest of the microorganisms in NPS or TS ( Figure 5 ). A negative relationship was observed between aligned viral reads and corresponding RT-PCR E-gene Ct value (R 2 =0.45) using an exponential regression model ( Figure S2a reads was calculated to be the optimum number of reads to achieve the highest sensitivity and specificity of any clinical sample, regardless of the anatomical sampling site ( Figure S2b ). (1/29) with a breadth of coverage of 98.3% ( Figure S3c ). One sample was assigned as part of the D lineage (1/29), and one as the A.1 lineage (Figure 8 ). Out of this, 23 samples were properly identified using the phylogenomics tree generated and the PANGO-Lineage assigner. Overall, the mNGS workflow identified one VOC and two samples with a single VOI (Table S6 ). This study has provided evidence that the mNGS workflow can detect a significant shift in the overall Overall, metagenomics sequencing can be adapted for the current ongoing COVID-19 pandemic as well as emerging viral pandemic threats. All sequencing results are available at the European Nucleotide Archive (ENA) (Project ID ERP132183; sequencing sample IDs ERS7669237 -ERS7669486). A comprehensive review of COVID-19 characteristics Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England Metagenomics: preventing future pandemics Laboratory validation of a clinical metagenomic sequencing assay for pathogen detection in cerebrospinal fluid Metagenomic Next-Generation Sequencing versus Traditional Pathogen Detection in the Diagnosis of Peripheral Pulmonary Infectious Lesions The diagnostic value of metagenomic next•generation sequencing in infectious diseases Pathogenic Detection by Metagenomic Next-Generation Sequencing in Osteoarticular Infections Metagenomic Next-Generation Sequencing of Nasopharyngeal Specimens Collected from Confirmed and Suspect COVID-19 Patients Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens SARS-CoV-2 and co-infections detection in nasopharyngeal throat swabs of COVID-19 patients by metagenomics Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: a comparison of patients with and without COVID-19 Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome Outcomes of respiratory viral-bacterial co-infection in adult hospitalized patients Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance Rapid metagenomic characterization of a case of imported COVID-19 in Cambodia IDseq-An open source cloud-based pipeline and analysis service for metagenomic pathogen detection and monitoring STAR: ultrafast universal RNA-seq aligner Trimmomatic: a flexible trimmer for Illumina sequence data cov-lineages/pangolin. (CoV-lineages Development and validation of RT-PCR assays for testing for SARS-CoV-2 The active lung microbiota landscape of COVID-19 patients Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients Co-infections in people with COVID-19: a systematic review and meta-analysis When two for the price of one isn't a bargain: estimating prevalence and microbiology of bacterial co-infections in patients with COVID-19 Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting A rapid, cost efficient and simple method to identify current SARS-CoV-2 variants of concern by Sanger sequencing part of the spike protein gene HiSpike: A high-throughput cost effective sequencing method for the SARS-CoV-2 spike gene The alphadiversity analysis was evaluated using a pairwise Kruskal-Wallis test. The beta-diversity analysis was Figure 2. Alpha-and beta-diversity analysis of the DNA-metagenome. (a-f) Beta-diversity principal coordinate analysis (PCoA) plots were compared between the Bray-Curtis quantitative metric vs the Jaccard qualitative metric and a PERMANOVA was computed with 999 permutations in each pairwise comparison. (a) PCoAs by SARS-CoV-2 diagnostic status PCoAs by SARS-CoV-2 diagnosis status amongst asymptomatic patients and NPS samples. (f) PCoAs by SARS-CoV-2 diagnosis status amongst patients with symptoms and TS samples. (g-l) Alpha-diversity Shannon index with a pairwise Kruskal-Wallis test. (g) Shannon comparison by SARS-CoV-2 diagnostic status Shannon comparison by body site sampling. (j) Shannon comparison by SARS-CoV-2 diagnosis status amongst patients with symptoms and NPS samples. (k) Shannon comparison by SARS-CoV-2 diagnosis status amongst asymptomatic patients and NPS samples. (l) Shannon comparison by SARS-CoV-2 diagnosis status amongst patients with symptoms and TS samples PCoAs by SARS-CoV-2 diagnosis status amongst asymptomatic patients and NPS samples PCoAs by SARS-CoV-2 diagnosis status amongst patients with symptoms and TS samples Shannon comparison by SARS-CoV-2 diagnostic status. (h) Shannon comparison by symptomatology status. (i) Shannon comparison by body site sampling. (j) Shannon comparison by SARS-CoV-2 diagnosis status amongst patients with symptoms and NPS samples. (k) Shannon comparison by SARS-CoV-2 diagnosis status amongst asymptomatic patients and NPS samples. (l) Shannon comparison by SARS-CoV-2 diagnosis status amongst patients with symptoms and TS samples. the next closest node. Clinical isolates are depicted with its patient ID. Black labels depict the samples which lineage was identified with Pangolin COVID-19 Lineage assigner We would like to thank the participants of the study. We would like to thank Paul Gordon and Elizabeth Fashbender for their valuable input in the study design. We also thank technologists at Alberta Precision Laboratories for sample processing.